In contrast to the Mammaprint assay, the 21-gene recurrence score (RS; Oncotype DX, Genomic Health) was established based on a candidate gene approach in estrogen-receptor positive (ER+) breast cancer patients [17]. The gene discussed is ESR1; the disease is breast cancer.